eligibility_summary
Consent/HIPAA required. Biopsy-proven DLBCL in first relapse (high-grade B-cell allowed, not Burkitt), ECOG 0-2, radiologic activity within 28 days, only 1 prior line, >=14 days since last therapy with <=Grade 1 toxicities, transplant eligible or not, adequate pulmonary reserve (dyspnea <=G1, SpO2>91%). Exclude: serious infections, >mild or function-limiting hearing loss, pregnant/breastfeeding or planning pregnancy within 1 yr, prior polatuzumab, severe mAb allergy, contraindication to gemcitabine/cisplatin/dexamethasone, symptomatic cardiac disease/LVEF<40%, other cancers allowed if non-interfering.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in first‑relapse rrDLBCL testing PV‑RGDP: polatuzumab vedotin (antibody‑drug conjugate, anti‑CD79b delivering MMAE to malignant B cells, disrupting microtubules), rituximab (anti‑CD20 monoclonal antibody inducing B‑cell depletion via CDC/ADCC), gemcitabine (antimetabolite nucleoside analog inhibiting DNA synthesis), cisplatin (platinum DNA crosslinker), dexamethasone (glucocorticoid inducing lymphocyte apoptosis/anti‑inflammatory), hyaluronidase (enzyme degrading hyaluronan to enhance subcutaneous drug dispersion), and G‑CSF (growth factor promoting neutrophil production). Targets/pathways: CD79b/BCR+ and CD20+ B cells, microtubules, DNA replication/repair, glucocorticoid receptor, CSF3R/JAK‑STAT, hyaluronan matrix.